Allergy Therapeutics Plc has received a public opening position disclosure/dealing disclosure from Cavendish Securities Plc, an exempt principal trader. The disclosure is made in accordance with Rule 8.5 of the Takeover Code. Cavendish Securities Plc is connected to Allergy Therapeutics Plc, the offeror/offeree in question. The date of the position held/dealing undertaken is 13/10/2023.

In terms of positions, Cavendish Securities Plc owns and/or controls 41,644 relevant securities of Allergy Therapeutics Plc, which represents 0.01% of the total. There are no cash-settled derivatives or stock-settled derivatives (including options) and agreements to purchase/sell.

Regarding dealings, Cavendish Securities Plc has made sales of 200,000 securities of Allergy Therapeutics Plc at a highest price per unit of 1.39 and a lowest price per unit of 1.39. There are no cash-settled derivative transactions or stock-settled derivative transactions (including options) to report.

There are no indemnity or other dealing arrangements, agreements, arrangements, or understandings relating to options or derivatives. No supplemental form 8 (open positions) is attached to the disclosure. The date of disclosure is 16/10/2023, and the contact name is Nancy Dyer with a telephone number of 0207 220 0594.